Table 4.
Monitored Blood Labs
| 0w | 2w | 4w | 8w | 12w | 16w | |
|---|---|---|---|---|---|---|
| Alanine transaminase (ALT; U/L) | ||||||
| YAG | 17.1 ± 5.8 | 16.5 ± 5.9 | - | - | - | - |
| (N = 11) | p > .99 | |||||
| OAG (N = 12 for 0w, | 24.6 ± 9.6 | 25.1 ± 10.2 | 25.5 ± 11.4 | 23.2 ± 13.8 | 24.9 ± 18.6 | 25.2 ± 19.3 |
| 2w; N = 11 for 4w, | p > .99 | p > .99 | p > .99 | p > .99 | p > .99 | |
| 8w, 12w, 16w) | ||||||
| OAP (N = 12) | 23.0 ± 9.0 | 23.8 ± 10.1 p > .99 |
22.1 ± 7.5 p > .99 |
23.1 ± 7.6 p > .99 |
20.8 ± 4.2 p > .99 |
24.9 ± 8.3 p > .99 |
| Aspartate transaminase (AST; U/L) | ||||||
| YAG | 18.3 ± 8.2 | 20.1 ± 10.2 | - | - | - | - |
| (N = 11) | p > .99 | |||||
| OAG (N = 12 for 0w, | 21.9 ± 3.8 | 23.9 ± 7.4 | 21.3 ± 7.1 | 20.5 ± 6.6 | 22.6 ± 8.9 | 25.2 ± 9.6 |
| 2w; N = 11 for 4w, | p > .99 | p > .99 | p > .99 | p > .99 | p > .99 | |
| 8w, 12w, 16w) | ||||||
| OAP (N = 12) | 24.2 ± 6.3 | 23.9 ± 8.2 | 19.9 ± 8.2 | 20.0 ± 6.2 | 20.1 ± 6.8 | 23.4 ± 9.5 |
| p > .99 | p = .27 | p = .38 | p > .99 | p > .99 | ||
| Creatinine (mg/dl) | ||||||
| YAG | 0.9 ± 0.2 | 0.8 ± 0.2 | - | - | - | - |
| (N = 11) | p = .44 | |||||
| OAG (N = 12 for 0w, 2w; N = 11 for 4w, 8w, 12w, 16w) |
0.9 ± 0.2 | 0.9 ± 0.2 p > .99 |
0.9 ± 0.2 p > .99 |
1.0 ± 0.3 p > .99 |
1.0 ± 0.3 p > .99 |
0.9 ± 0.2 p > .99 |
| OAP (N = 12) | 0.8 ± 0.2 | 0.9 ± 0.2 | 0.9 ± 0.2 | 0.9 ± 0.2 | 0.8 ± 0.1 | 0.8 ± 0.1 |
| p > .99 | p = .10 | p > .99 | p > .99 | p > .99 |
Notes: Data are summarized by means with standard deviations. p Values compare means estimated by the general linear mixed regression model. 2w, 4w, 8w, 12w, 16w refer to weeks after receiving supplements. p = compared to 0w.